Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department

Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomić Aleksandra, Vujović Balša, Svetel Marina, Dragašević-Mišković Nataša, Petrović Igor, Pekmezović Tatjana, Kostić Vladimir S.
Format: Article
Language:English
Published: Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade 2015-01-01
Series:Vojnosanitetski Pregled
Subjects:
Online Access:http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501500114T.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850254708580548608
author Tomić Aleksandra
Vujović Balša
Svetel Marina
Dragašević-Mišković Nataša
Petrović Igor
Pekmezović Tatjana
Kostić Vladimir S.
author_facet Tomić Aleksandra
Vujović Balša
Svetel Marina
Dragašević-Mišković Nataša
Petrović Igor
Pekmezović Tatjana
Kostić Vladimir S.
author_sort Tomić Aleksandra
collection DOAJ
description Background/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. Мethods. А hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3-4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ≥ 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ≥ 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ± 27.5% and 54.1 ± 28.3%), respectively than the graphospasm group (26.7 ± 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ± 18.6 days after the first treatment and 32.5 ± 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well-tolerated side-effects. [Projekat Ministarstva nauke Republike Srbije, br. 175090]
format Article
id doaj-art-59c7bfb8a5934551823903090406c633
institution OA Journals
issn 0042-8450
2406-0720
language English
publishDate 2015-01-01
publisher Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
record_format Article
series Vojnosanitetski Pregled
spelling doaj-art-59c7bfb8a5934551823903090406c6332025-08-20T01:57:04ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502406-07202015-01-0172121069107310.2298/VSP131224114T0042-84501500114TEfficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients DepartmentTomić Aleksandra0Vujović Balša1Svetel Marina2Dragašević-Mišković Nataša3Petrović Igor4Pekmezović Tatjana5Kostić Vladimir S.6Clinical Center of Serbia, Clinic for Neurology, BelgradeClinical Center of Montenegro, Clinic for Neurology, Podgorica, MontenegroClinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, BelgradeClinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, BelgradeClinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, BelgradeFaculty of Medicine, Institute of Epidemiology, BelgradeClinical Center of Serbia, Clinic for Neurology, Belgrade + Faculty of Medicine, BelgradeBackground/Aim. Botulinum toxin (BTX) irreversibly inhibits presynaptic acetylcholine release with subsequent relaxation of abnormally contracting muscles. It is an effective and well tolerated treatment with long-term benefit in a variety of movement disorders and other neurological and non-neurological disturbances. The aim of our study was to present our experience with BTX type A in treatment of different forms of focal dystonias. Мethods. А hundred of patients with different focal dystonias (spastic torticollis, blepharospasm and graphospasm) from the Botulinum Toxin Outpatients Department, Clinic for Neurology, Clinical Center of Serbia, were included in the study. All the patients were examined and rated at baseline visit prior to BTX application and on the following visit, after 3-4 months, using self-assessment improvement questionnaire and standardized rating scales. Results. The improvement of ≥ 50% was presented in 68.2% of all (199) the analyzed applications. Independent predictors of good response to the therapy (improvement ≥ 50%) were male sex (p = 0.011), the presence of sensory trick (p = 0.013) and the total number of BTX applications (p = 0.002). The patients with spastic torticollis and blepharospasm showed a statistically significantly better BTX effect (improvement 57.3 ± 27.5% and 54.1 ± 28.3%), respectively than the graphospasm group (26.7 ± 25.6%). Most of the patients did not have therapy complications (81.4% and 72% in two applications). Side effects in the remaining patients (muscle weakness, dysphagia, ptosis, double vision, neck weakness and lacrimal dysfunction) lasted for 28.3 ± 18.6 days after the first treatment and 32.5 ± 36.2 days after the second one. Conclusion. BTX is safe and highly effective in long-term treatment of patients with different forms of focal dystonia, with only mild and well-tolerated side-effects. [Projekat Ministarstva nauke Republike Srbije, br. 175090]http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501500114T.pdfdystoniabotulinum toxinsSerbiaquestionnairesquality of life
spellingShingle Tomić Aleksandra
Vujović Balša
Svetel Marina
Dragašević-Mišković Nataša
Petrović Igor
Pekmezović Tatjana
Kostić Vladimir S.
Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
Vojnosanitetski Pregled
dystonia
botulinum toxins
Serbia
questionnaires
quality of life
title Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
title_full Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
title_fullStr Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
title_full_unstemmed Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
title_short Efficacy of Botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: Experience of the Botulinum Toxin Outpatients Department
title_sort efficacy of botulinum toxin type a in treatment of different forms of focal dystonias in the serbian population experience of the botulinum toxin outpatients department
topic dystonia
botulinum toxins
Serbia
questionnaires
quality of life
url http://www.doiserbia.nb.rs/img/doi/0042-8450/2015/0042-84501500114T.pdf
work_keys_str_mv AT tomicaleksandra efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT vujovicbalsa efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT svetelmarina efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT dragasevicmiskovicnatasa efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT petrovicigor efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT pekmezovictatjana efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment
AT kosticvladimirs efficacyofbotulinumtoxintypeaintreatmentofdifferentformsoffocaldystoniasintheserbianpopulationexperienceofthebotulinumtoxinoutpatientsdepartment